HC Wainwright restated their buy rating on shares of Sarepta Therapeutics (NASDAQ:SRPT) in a report issued on Tuesday. HC Wainwright currently has a $75.00 price objective on the biotechnology company’s stock.

A number of other research firms have also commented on SRPT. Oppenheimer reaffirmed a buy rating and set a $76.00 price target on shares of Sarepta Therapeutics in a research report on Monday, October 16th. BidaskClub raised shares of Sarepta Therapeutics from a hold rating to a buy rating in a report on Monday, December 25th. Zacks Investment Research lowered shares of Sarepta Therapeutics from a hold rating to a sell rating in a report on Friday, January 5th. Morgan Stanley raised shares of Sarepta Therapeutics from an equal weight rating to an overweight rating and set a $60.00 target price on the stock in a report on Monday, October 2nd. Finally, Robert W. Baird reissued an outperform rating and issued a $101.00 target price on shares of Sarepta Therapeutics in a report on Monday, October 2nd. Two investment analysts have rated the stock with a sell rating, four have given a hold rating and eighteen have issued a buy rating to the company. The company presently has an average rating of Buy and an average target price of $63.88.

Sarepta Therapeutics (SRPT) opened at $61.52 on Tuesday. Sarepta Therapeutics has a 1 year low of $26.26 and a 1 year high of $61.89. The company has a market cap of $3,980.00, a PE ratio of -30.16 and a beta of 1.37. The company has a debt-to-equity ratio of 0.04, a quick ratio of 9.52 and a current ratio of 10.44.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings results on Wednesday, October 25th. The biotechnology company reported ($0.20) EPS for the quarter, topping analysts’ consensus estimates of ($0.86) by $0.66. Sarepta Therapeutics had a negative net margin of 112.08% and a negative return on equity of 51.72%. The business had revenue of $45.95 million for the quarter, compared to analyst estimates of $41.29 million. During the same period last year, the firm earned ($0.95) earnings per share. analysts anticipate that Sarepta Therapeutics will post -3.07 EPS for the current year.

In other news, SVP Shamim Ruff sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, November 6th. The shares were sold at an average price of $55.00, for a total value of $550,000.00. Following the sale, the senior vice president now directly owns 37,045 shares in the company, valued at approximately $2,037,475. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Douglas S. Ingram purchased 38,138 shares of Sarepta Therapeutics stock in a transaction dated Wednesday, November 8th. The stock was bought at an average price of $52.44 per share, for a total transaction of $1,999,956.72. Following the completion of the purchase, the chief executive officer now owns 420,196 shares in the company, valued at approximately $22,035,078.24. The disclosure for this purchase can be found here. Company insiders own 9.60% of the company’s stock.

Several institutional investors and hedge funds have recently bought and sold shares of SRPT. Ameritas Investment Partners Inc. boosted its stake in shares of Sarepta Therapeutics by 6.3% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 4,561 shares of the biotechnology company’s stock valued at $154,000 after purchasing an additional 271 shares in the last quarter. Cubist Systematic Strategies LLC boosted its position in Sarepta Therapeutics by 116.4% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 4,600 shares of the biotechnology company’s stock worth $155,000 after buying an additional 2,474 shares during the period. Ladenburg Thalmann Financial Services Inc. boosted its position in Sarepta Therapeutics by 140.9% during the 3rd quarter. Ladenburg Thalmann Financial Services Inc. now owns 4,262 shares of the biotechnology company’s stock worth $193,000 after buying an additional 2,493 shares during the period. Fox Run Management L.L.C. acquired a new stake in Sarepta Therapeutics during the 3rd quarter worth approximately $204,000. Finally, Bayesian Capital Management LP acquired a new stake in Sarepta Therapeutics during the 2nd quarter worth approximately $206,000. Institutional investors own 82.02% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This article was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this article on another website, it was illegally copied and reposted in violation of United States and international copyright law. The legal version of this article can be read at https://www.thecerbatgem.com/2018/01/13/hc-wainwright-reaffirms-buy-rating-for-sarepta-therapeutics-srpt.html.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).

Analyst Recommendations for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.